←RETURN TO 2026 IPO RADAR DECK (135 OFFERINGS)COHORT STANDING: #3 of 135
Verified SEC Filing/Calendar Year 2026
NASDAQHealth Care
$COAG
MOONSHOT (>+50%)
Hemab Therapeutics Holdings, Inc.
OFFER PRICE$20.00
CURRENT PRICE
$53.56
CUMULATIVE RETURN
+167.78%
PRICING DATE: 5/1/2026SEC FILING SNAPSHOT
SECTION 01 // FORENSIC TEARDOWN
The Seagull Executive Verdict
SURVIVAL RATING: WINNER
WHAT THE BUSINESS DOES
Hemab Therapeutics Holdings, Inc. sells products and services in the Health Care market. The company went public in 2026 to raise cash from public stock markets.
THE WALL STREET PITCH
Bankers told everyday buyers that Hemab Therapeutics Holdings, Inc. would grow fast and dominate its market.
THE COLD REALITY
The stock climbed 167.78% after the IPO, holding value better than many other 2026 listings.
SECTION 02 // CAPITAL ALLOCATION
Capital Formation & Float Scarcity
FLAG: TREASURY GROWTH
Gross Proceeds
$150.0M
Cash extracted from market
Post-Money Value
Undisclosed
Total company valuation
Public Float %
18.5%
Shares available to public
Secondary Share %
0%
Insider cash extraction
CAPITAL USE ANALYSIS
Standard primary capital raise for general working capital.
SECTION 03 // SUPPLY SHOCK AUDITOR
Insider Lock-Up Expiration
VC DUMP RISK: MODERATE
Expiration Calendar Date
2026-10-28
LOCKUP EXPIRED
Supply Shock Multiplier
N/A
Float expansion ratio upon unlock
Lockup Duration
180 Days
Contractual restriction window
SECTION 05 // COHORT BENCHMARK
Sector Peer & Cohort Telemetry
RANK: #3 of 135
2026 Cohort Standing
#3 of 135
Out of 135 total 2026 IPO offerings
Sector Median Return
+21.64%
Health Care sector midpoint
Sector Win Rate
78%
% of peer IPOs trading in profit
PERFORMANCE VS PEERS
Hemab Therapeutics Holdings, Inc. is currently trading above the Health Care sector median of 21.64%. Across the entire 2026 calendar year cohort, only 78% of Health Care offerings have sustained a positive return above their initial offer price.